LBPH - שולי רווח תפעולי Longboard

Longboard Pharmaceuticals focuses on developing therapies for rare epilepsies through the activation of 5-HT2C receptors. The current operating margin confirms the strength of this strategic direction, with the 0.00 mark reflecting the latest data. The business is based on the development of current drugs in clinical trial phases and demonstrates high resilience to macroeconomic shocks due to the non-cyclical nature of the biopharmaceutical sector.
פילוחים אנליטיים של חברת Longboard Pharmaceuticals

To objectively evaluate the issuer, it is essential for the manager to understand the operating margin, which measures the share of profit from core business operations in total revenue before taxes and interest. An analysis of the operating profitability of operational processes, with a current value of 0.00, demonstrates effective cost management, which is critically important for Longboard Pharmaceuticals (LBPH) when developing costly drugs for the treatment of rare pediatric neurological pathologies.